Engineered immune cells for recurrent brain cancer
Part of Cancer clinical trials.
This trial tests a new therapy where your own immune cells are modified to attack brain tumor cells while also blocking a protein that helps tumors hide. It is for patients with a specific type of aggressive brain cancer that has come back after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a recurrent aggressive brain tumor (grade 4 glioblastoma).
- You are at least 18 years old.
- You are able to care for yourself and are out of bed more than half the day (ECOG 0-2).
- Your doctor expects you to live longer than 3 months.
- You have not had prior treatment with immune checkpoint inhibitors or other immunotherapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Hear when a new Recurrent Malignant Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.